Clinical trial · Observational
CD180 Overexpression in Follicular Lymphoma
CD180 Overexpression in Follicular Lymphoma Is Restricted to the Lymph Node Compartment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background:Altered Toll-like receptor (TLR) expression levels and/or mutations in its signaling pathway (such as MyD88 mutation) contribute to the pathogenesis of lymphoproliferative disorders (LPD). CD180 is an orphan member of the TLR family that modulates the signaling of several TLRs, but only limited studies have evaluated its expression by flow cytometry (FCM) in LPD. Methods: Using a multiparameter FCM approach, biologists have assessed CD180 mean fluorescence intensity (MFI) in lymph nodes (LNs) and peripheral blood (PB) samples obtained from patients with follicular lymphoma (FL; LN/PB, n=44/n=15), chronic lymphocytic leukemia (CLL, n=26/n=21), mantle cell lymphoma (MCL, n=13/n=17), and marginal zone lymphoma (MZL, n=16/n=12). Specimens from non-tumoral PB and LN (n=8/n=12) were used as controls.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- LN Lymph nodes
- description
- Samples obtained from patients with : LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells
- label
- PB peripheral blood
- description
- Samples obtained from patients with : LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells
Primary outcomes (2)
- measure
- Immunophenotype Analysis by Flow Cytometry of lymph nodes samples at inclusion
- timeFrame
- At inclusion, day 0.
- description
- Using a multiparameter FCM approach, biologists assessed the CD180 expression by our routine antigen panel in LN suspensions as well as in PB samples. Samples were analyzed on a BD FACSCanto II cytometer (BD FACS DIVA software; Becton Dickinson, San Jose, CA).
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Samples from patients with: * LF: Follicular lymphoma * MCL: Mantle cell lymphoma * CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia * MZL : splenic marginal zone * Clt :control B-cells Exclusion Criteria: * Patient \<18 years old
References
Publications (1)
- RESULTMestrallet F, Sujobert P, Sarkozy C, Traverse-Glehen A, Callet-Bauchu E, Magaud JP, Salles G, Baseggio L. CD180 overexpression in follicular lymphoma is restricted to the lymph node compartment. Cytometry B Clin Cytom. 2016 Sep;90(5):433-9. doi: 10.1002/cyto.b.21331. Epub 2015 Dec 11. PMID 26482097